Neuren Pharmaceuticals Ltd (NEU)

Sydney
3.740
-0.060(-1.58%)
  • Volume:
    73,174
  • Bid/Ask:
    3.740/3.800
  • Day's Range:
    3.730 - 3.860

NEU Overview

Prev. Close
3.8
Day's Range
3.73-3.86
Revenue
40K
Open
3.73
52 wk Range
1.51-4.68
EPS
-0.07
Volume
73,174
Market Cap
471.11M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
120,003
P/E Ratio
-
Beta
2.2
1-Year Change
127.36%
Shares Outstanding
125,965,676
Next Earnings Date
22 Aug 2022
What is your sentiment on Neuren Pharma?
or
Market is currently closed. Voting is open during market hours.

Neuren Pharmaceuticals Ltd News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Neuren Pharmaceuticals Ltd Company Profile

Neuren Pharmaceuticals Ltd Company Profile

Employees
0
Market
Australia

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company that is engaged in developing drugs for neurological disorders. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The Company has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The Company is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellNeutralBuyBuy
Technical IndicatorsStrong SellStrong SellNeutralStrong BuyStrong Buy
SummaryStrong SellStrong SellNeutralStrong BuyStrong Buy